Adjuvant combination leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin (FOLFIRINOX) and other multiagent chemotherapy regimens boost overall survival (OS) in patients with ...
Investigators presented initial results from a phase 3 trial of adjuvant durvalumab plus tremelimumab for resected primary renal cell carcinoma (RCC).
“ur finding enables the safe discontinuation of follow-up after 6 years, leading to an improvement in quality of life and a reduction in health care system costs,” study researchers wrote.
(Barcelona, Spain September 8, 2025, 10:45 a.m. CEST / UTC +2) – Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant ...
Patel discusses the design and patient criteria for the pivotal C-POST trial evaluating adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma. In an interview with Targeted Oncology, ...
Data gathered up to day 57 after the second dose indicated that VLA1601 was generally well tolerated and safe across all ...
Overall survival outcomes in stage III melanoma patients treated with adjuvant immunotherapy vs targeted therapy: A National Cancer Database analysis. This is an ASCO Meeting Abstract from the 2025 ...
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is ...
Topline results from the IMvigor011 trial show that ctDNA-guided adjuvant atezolizumab improves survival in patients with MIBC. Adjuvant atezolizumab in patients who are ctDNA-positive after radical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback